Neurocrine Biosciences (NBIX) Price to FCF (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Price to FCF for 17 consecutive years, with 133.15 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to FCF fell 4.23% year-over-year to 133.15; the trailing twelve-month figure through Jun 2026 stood at 19.67 (down 16.41% YoY), and the FY2025 full-year result was 18.96, down 22.13% from the prior year.
• Price to FCF climbed to 133.15 in Q2 2026 per NBIX's latest filing, from 96.95 in the prior quarter.
• Across five years, Price to FCF topped out at 262.09 in Q2 2024 and bottomed at 186.14 in Q1 2022.
• Historically, Price to FCF has averaged 77.78 across 5 years, with a median of 79.71 in 2022.
• The sharpest annual moves came in 2022 and 2024: Price to FCF tumbled 267.7% in 2022, then soared 392.08% in 2024.
• Over 5 years, Price to FCF stood at 81.63 in 2022, then soared by 34.9% to 110.12 in 2023, then tumbled by 47.61% to 57.69 in 2024, then slumped by 37.03% to 36.33 in 2025, then surged by 266.53% to 133.15 in 2026.
• According to Business Quant data, Price to FCF over the past three periods registered 133.15, 96.95, and 36.33 for Q2 2026, Q1 2026, and Q4 2025 respectively.